Akari Therapeutics (AKTX) Price & Analysis

Compare

316 Followers

AKTX Stock Chart & Stats

$0.45

-$0.09(-6.73%)

At close: Jan 08 4:00 PM EST

$0.45

-$0.09(-6.73%)

Day’s Range― - ―

52-Week Range$0.29 - $1.73

Previous CloseN/A

Volume16.29K

Average Volume (3M)933.62K

Market Cap

$11.06M

Enterprise Value$35.60M

Total Cash (Recent Filing)$2.48M

Total Debt (Recent Filing)$2.12M

Price to Earnings (P/E)―

Beta0.81

Next Earnings

Apr 07, 2026

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding35,739,730

10 Day Avg. Volume1,846,827

30 Day Avg. Volume933,621

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)<0.01

Price to Sales (P/S)0.00

P/FCF Ratio>-0.01

Enterprise Value/Market Cap3.22

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-35.60K

Enterprise Value/Ebitda-2.16

Forecast

1Y Price Target

$4.53

Price Target Upside906.67% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.39

Revenue Forecast (FY)$3.54M

Bulls Say, Bears Say

Bulls Say

Preclinical DataAkari announced preclinical data demonstrating activity of its antibody drug conjugate (ADC) novel payload PH1 in prostate cancer, particularly in the presence of AR-V7, a splice variant of the androgen receptor that is a key driver of progression of metastatic castration resistant prostate cancer (mCRPC).

Product DevelopmentAkari Therapeutics is rated as a Buy with a price target of $5.00.

Therapeutic AdvancementsThere is potential with Androgen Receptor Pathway Inhibitors in Akari Therapeutics' ADC Payload for prostate cancer.

Bears Say

Financial RiskThe company's weak balance sheet may present a significant risk.

Funding ConcernsThe financial overhang may weigh on the stock until the company is able to secure additional funds.

Akari Therapeutics News

Akari Therapeutics announces preclinical data on AKTX-101

Akari Therapeutics (AKTX) announced key preclinical data demonstrating the therapeutic potential of its novel ADC targeting Trop2, AKTX-101,...

24h ago

AKTX

Akari Therapeutics provides update, highlights ADC payload innovation

Akari Therapeutics (AKTX) announced the publication of a new CEO Corner segment. For this segment, Abizer Gaslightwala, CEO...

6d ago

AKTX

Akari Therapeutics appoints Farag as interim CFO

Akari Therapeutics (AKTX) announced the appointment of Kameel Farag as its Interim Chief Financial Officer who joined Akari...

22d ago

AKTX

Akari Therapeutics announces presentation of mechanism of action data for PH1

Akari Therapeutics (AKTX) announced the presentation of immune mechanism-of-action data for its novel ADC payload, PH1. The Company...

30d ago

AKTX

Akari Therapeutics Prepares Investor Presentation for Conferences

Akari Therapeutics ( ($AKTX) ) just unveiled an announcement. On December 8, 2025, Akari Therapeutics, Plc prepared an...

2d ago

AKTX

Akari Therapeutics Faces Nasdaq Delisting Notice

Akari Therapeutics ( ($AKTX) ) has issued an announcement. On November 24, 2025, Akari Therapeutics received a notification...

14d ago

AKTX

Akari Therapeutics announces abstract on PH1 mechanism-of-action data

Akari Therapeutics (AKTX) announced its abstract highlighting immune mechanism-of-action data for its novel ADC payload, PH1. The abstract...

1M ago

AKTX

Akari Therapeutics announces formation of SAB

Akari Therapeutics (AKTX) announced the formation of its Scientific Advisory Board, SAB, and inaugural appointment of Dr. Sara...

1M ago

AKTX

Akari Therapeutics Appoints Kameel Farag as Interim CFO

The latest announcement is out from Akari Therapeutics ( ($AKTX) ). On October 22, 2025, Akari Therapeutics appointed...

2M ago

AKTX

Akari Therapeutics launches CEO Corner platform

Akari Therapeutics (AKTX) announced the launch of its CEO Corner featuring Abizer Gaslightwala, President and CEO of Akari....

2M ago

AKTX

Akari Therapeutics Announces $2.5 Million Direct Offering

Akari Therapeutics ( ($AKTX) ) has issued an announcement. On October 14, 2025, Akari Therapeutics entered into a...

2M ago

AKTX

Akari Therapeutics Announces $2.5 Million Direct Offering

An update from Akari Therapeutics ( ($AKTX) ) is now available. On October 15, 2025, Akari Therapeutics announced...

2M ago

AKTX

Akari Therapeutics prices 3.13M ADSs at 80c in registered direct offering

Akari Therapeutics (AKTX) entered into a definitive agreement for the issuance and sale of an aggregate of 3,125,000...

2M ago

AKTX

Akari Therapeutics files two new patents with USPTO

Akari Therapeutics (AKTX) announced that it has filed two new provisional patent applications with the United States Patent...

2M ago

AKTX

AKTX FAQ

What was Akari Therapeutics PLC (ADR)’s price range in the past 12 months?

Akari Therapeutics PLC (ADR) lowest stock price was $0.29 and its highest was $1.73 in the past 12 months.

What is Akari Therapeutics PLC (ADR)’s market cap?

Akari Therapeutics PLC (ADR)’s market cap is $11.06M.

When is Akari Therapeutics PLC (ADR)’s upcoming earnings report date?

Akari Therapeutics PLC (ADR)’s upcoming earnings report date is Apr 07, 2026 which is in 118 days.

How were Akari Therapeutics PLC (ADR)’s earnings last quarter?

Akari Therapeutics PLC (ADR) released its earnings results on Sep 25, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.03.

Is Akari Therapeutics PLC (ADR) overvalued?

According to Wall Street analysts Akari Therapeutics PLC (ADR)’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Akari Therapeutics PLC (ADR) pay dividends?

Akari Therapeutics PLC (ADR) does not currently pay dividends.

What is Akari Therapeutics PLC (ADR)’s EPS estimate?

Akari Therapeutics PLC (ADR)’s EPS estimate is -0.06.

How many shares outstanding does Akari Therapeutics PLC (ADR) have?

Akari Therapeutics PLC (ADR) has 35,739,730 shares outstanding.

What happened to Akari Therapeutics PLC (ADR)’s price movement after its last earnings report?

Akari Therapeutics PLC (ADR) reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went up 0.901%.

Which hedge fund is a major shareholder of Akari Therapeutics PLC (ADR)?

Currently, no hedge funds are holding shares in AKTX

Company Description

Akari Therapeutics PLC (ADR)

Akari Therapeutics Plc is a biopharmaceutical company focused on developing innovative treatments for rare and orphan diseases, particularly those involving severe inflammatory and allergic conditions. The company operates in the biotechnology sector, with its core products centered around inhibitors of the complement and leukotriene systems, which play a crucial role in the body's immune response.

Akari Therapeutics (AKTX) Earnings & Revenues

Historic Earnings Reports

AKTX Stock 12 Month Forecast

Average Price Target

$4.53

▲(906.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","33":"$33","-1":"-$1","7.5":"$7.5","24.5":"$24.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,7.5,16,24.5,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2022","6":"Dec<br/>2024","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.75,1.2307692307692308,1.7115384615384617,2.1923076923076925,2.6730769230769234,3.1538461538461537,3.6346153846153846,4.115384615384615,4.596153846153847,5.076923076923077,5.5576923076923075,6.038461538461538,6.519230769230769,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.75,1.040769230769231,1.3315384615384616,1.6223076923076922,1.9130769230769231,2.203846153846154,2.4946153846153845,2.7853846153846153,3.0761538461538462,3.366923076923077,3.657692307692308,3.9484615384615385,4.239230769230769,{"y":4.53,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.75,0.8153846153846154,0.8807692307692307,0.9461538461538461,1.0115384615384615,1.0769230769230769,1.1423076923076922,1.2076923076923078,1.273076923076923,1.3384615384615386,1.4038461538461537,1.4692307692307693,1.5346153846153847,{"y":1.6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.4,"date":1598918400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.4,"date":1617235200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.4,"date":1625097600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.42,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1669852800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >